Predicting Omalizumab Effectiveness in Chronic Rhinosinusitis with Nasal Polyps and Asthma
Author Information
Author(s): Sima Yutong, Zheng Ming, Zhao Yan, Ge Siqi, Liu Chengyao, Wang Ping, Wang Xiangdong, Zhang Luo
Primary Institution: Beijing Tongren Hospital, Capital Medical University
Hypothesis
Can inflammatory biomarkers predict the response to omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps and asthma?
Conclusion
Omalizumab significantly improves inflammatory mediators and can be predicted by specific biomarkers in patients with refractory chronic rhinosinusitis with nasal polyps and asthma.
Supporting Evidence
- 72.22% of patients showed significant improvement in SNOT-22 scores after treatment.
- Serum CCL-3 and CCL-4 levels predicted improvement in SNOT-22 scores.
- Significant decreases in inflammatory biomarkers were observed after 24 weeks of treatment.
Takeaway
This study found that certain markers in the blood and nasal secretions can help doctors know if a medicine called omalizumab will work for patients with a stuffy nose and asthma.
Methodology
Patients underwent evaluations and received omalizumab treatment for 24 weeks, with various biomarkers measured in nasal and serum samples.
Limitations
The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
Patients were adults with refractory chronic rhinosinusitis with nasal polyps and asthma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website